Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of JMKX003002 in hyperphosphatemia in hemodialysis patients with end-stage kidney disease
CTR20243906Phase 2Active
- Sponsor
- Zhejiang Hangyu Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of JMKX003002 in hyperphosphatemia (2 arms), sponsored by Zhejiang Hangyu Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
JMKX003002
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on CTR20243906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243906.